This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. (CHEST-1)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT00855465
First received: December 15, 2008
Last updated: October 14, 2016
Last verified: October 2016
Results First Received: November 4, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (Adempas, BAY63-2521)
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Only subjects with symptomatic chronic thromboembolic pulmonary hypertension (CTEPH) could participate in this study. CTEPH was defined either as inoperable or as persisting or recurrent PH after pulmonary endarterectomy.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
446 subjects were screened in 89 study centers in 26 countries worldwide. 184 of the 446 screened subjects were not randomized (adverse event [1], death [4], protocol violation [164], withdrawal by subject [15]). 262 of the 446 subjects were randomized. 261 of the 262 randomized subjects received study medication.

Reporting Groups
  Description
Riociguat (Adempas, BAY63-2521)_individual Dose Titration Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 16 weeks
Placebo Participants received Placebo orally as a film-coated tablet three times daily (tid) for 16 weeks

Participant Flow for 2 periods

Period 1:   Treatment Period
    Riociguat (Adempas, BAY63-2521)_individual Dose Titration   Placebo
STARTED   174   88 
Participants Received Treatment   173 [1]   88 
COMPLETED   160   83 
NOT COMPLETED   14   5 
Adverse Event                4                2 
Death                2                2 
Lack of Efficacy                2                1 
Non-compliance                1                0 
Protocol Violation                2                0 
Withdrawal by Subject                2                0 
Not treated                1                0 
[1] 1 subject randomized but not treated

Period 2:   Follow-up Period (FUP)
    Riociguat (Adempas, BAY63-2521)_individual Dose Titration   Placebo
STARTED   17 [1]   4 [1] 
COMPLETED   9   2 
NOT COMPLETED   8   2 
Adverse Event                0                1 
Death                0                1 
Lost to Follow-up                3                0 
Withdrawal by Subject                4                0 
Missing                1                0 
[1] Started FUP only if prematurely withdrawn from trt period or if not entering LTE study.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Riociguat (Adempas, BAY63-2521)_individual Dose Titration Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 16 weeks
Placebo Participants received Placebo orally as a film-coated tablet three times daily (tid) for 16 weeks
Total Total of all reporting groups

Baseline Measures
   Riociguat (Adempas, BAY63-2521)_individual Dose Titration   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 173   88   261 
Age 
[Units: Years]
Mean (Standard Deviation)
 59.3  (13.9)   59.2  (12.7)   59.3  (13.5) 
Gender 
[Units: Participants]
     
Female   118   54   172 
Male   55   34   89 
Race/Ethnicity, Customized 
[Units: Participants]
     
White   120   65   185 
Black or African American   7   1   8 
Asian   37   20   57 
Mixed   1   0   1 
Not reported   8   2   10 
Operability [1] 
[Units: Participants]
     
Inoperable CTEPH   121   68   189 
Postoperative CTEPH   52   20   72 
[1] CTEPH defined as inoperable or as persisting/recurrent PH after pulmonary endarterectomy (PEA).
Body Mass Index 
[Units: Kg/m^2]
Mean (Standard Deviation)
 27.13  (5.75)   27.73  (5.30)   27.33  (5.60) 
6-minute walking distance [1] 
[Units: Meters]
Mean (Standard Deviation)
 342.3  (81.9)   356.0  (74.7)   346.9  (79.7) 
[1] 6-minute walking distance (6MWD) is a measure for the objective evaluation of a participant's functional exercise capacity.
WHO (World Health Organization) functional class [1] 
[Units: Participants]
     
missing   0   1   1 
 3   0   3 
II   55   25   80 
III   107   60   167 
IV   8   2   10 
[1] The WHO functional assessment of pulmonary arterial hypertension ranged from functional class I (Patients with PH but without resulting limitation of physical activity) to class IV (Patients with PH with inability to carry out any physical activity without symptoms. These patients manifest signs of right-heart failure.). Changes to a lower WHO functional class resemble improvement; changes to a higher functional class resemble deterioration of pulmonary arterial hypertension (PAH).
Pulmonary vascular resistance [1] 
[Units: Dyn*s*cm^-5]
Mean (Standard Deviation)
 790.68  (431.57)   779.32  (400.94)   786.68  (420.21) 
[1] The pulmonary vascular resistance (PVR) is a calculated hemodynamic parameter. PVR is derived from the directly measured parameters mean pulmonary arterial pressure (PAPmean) and pulmonary capillary wedge pressure (PCWP), divided by the cardiac output (CO). PVR and PAPmean are acquired during a right heart catheterization. CO is a calculated hemodynamic parameter, too. Formula: PVR = 80*(PAPmean - PCWP)/CO


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

2.  Secondary:   Pulmonary Vascular Resistance (PVR) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

3.  Secondary:   N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

4.  Secondary:   World Health Organization (WHO) Functional Class - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

5.  Secondary:   Percentage of Participants With Clinical Worsening   [ Time Frame: At week 16 ]

6.  Secondary:   Borg CR 10 Scale - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

7.  Secondary:   EQ-5D Utility Score - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

8.  Secondary:   Living With Pulmonary Hypertension (LPH) Questionnaire - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

9.  Other Pre-specified:   All Caused Mortality   [ Time Frame: At visit 6 (week 16) ]

10.  Other Pre-specified:   Mean Pulmonary Artery Pressure (PAPmean) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

11.  Other Pre-specified:   Cardiac Index (CI) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

12.  Other Pre-specified:   Systolic Blood Pressure (SBP) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

13.  Other Pre-specified:   Diastolic Blood Pressure (DBP) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

14.  Other Pre-specified:   Heart Rate (HR) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

15.  Other Pre-specified:   Alanine Aminotransferase (ALT) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

16.  Other Pre-specified:   Aspartate Aminotransferase (AST) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

17.  Other Pre-specified:   Alkaline Phosphatase (AP) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

18.  Other Pre-specified:   Bilirubin - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

19.  Other Pre-specified:   Creatinine - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

20.  Other Pre-specified:   Creatinine Clearance - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

21.  Other Pre-specified:   Creatine Kinase (CK) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

22.  Other Pre-specified:   Erythrocytes (RBC) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

23.  Other Pre-specified:   Leukocytes (WBC) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

24.  Other Pre-specified:   Lymphocytes - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

25.  Other Pre-specified:   Neutrophils - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

26.  Other Pre-specified:   Hemoglobin - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

27.  Other Pre-specified:   Hematocrit - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

28.  Other Pre-specified:   Potassium - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

29.  Other Pre-specified:   Urate - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

30.  Other Pre-specified:   Urea (BUN) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

31.  Other Pre-specified:   Cystatin C - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

32.  Other Pre-specified:   Triacylglycerol Lipase - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

33.  Other Pre-specified:   Arterial Partial Pressure of Carbon Dioxide (PaCO2) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

34.  Other Pre-specified:   Arterial Partial Oxygen Pressure (PaO2) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

35.  Other Pre-specified:   Oxygen Saturation (SaO2) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

36.  Other Pre-specified:   Mean PR Duration (PRmean) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

37.  Other Pre-specified:   Mean QRS Duration (QRSmean) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

38.  Other Pre-specified:   Mean QT Duration (QTmean) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

39.  Other Pre-specified:   Mean QTcB Duration (Bazett's Correction Formula, QTcB) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

40.  Other Pre-specified:   Mean QTcF Duration (Fridericia's Correction Formula, QTcF) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

41.  Other Pre-specified:   Mean RR Duration (RRmean) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]

42.  Other Pre-specified:   Mean Ventricular Rate (VRmean) - Change From Baseline to Week 16   [ Time Frame: Baseline and week 16 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Therapeutic Area Head
Organization: Bayer
e-mail: clinical-trials-contact@bayerhealthcare.com


Publications of Results:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT00855465     History of Changes
Other Study ID Numbers: 11348
2007-000072-16 ( EudraCT Number )
Study First Received: December 15, 2008
Results First Received: November 4, 2013
Last Updated: October 14, 2016